Company: GANX
Filing Date: 2025-11-07
Form Type: S-3/A
Source: 0001104659-25-108472
Chunk: 45

Company: Gain Therapeutics, Inc.
Filing Date: 2025-11-07
Form: S-3/A
Chunk 45
---
 will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

<div align='center'>II-4</div>

TABLE OF CONTENTS

SIGNATURES Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Bethesda, Maryland, on this 7th day of November, 2025. GAIN THERAPEUTICS, INC. By: /s/ Gene Mack Name: Gene Mack
Title: Chief Executive Officer Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

| ​ 
 ​ 
 ​ | Signature         
 /s/ Gene Mack     
 ​                 
 Gene Mack         
 *                 
 ​                 
 Gianluca Fuggetta | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | Title                                                                      
 Chief Executive Officer and Director (Principal Executive Officer)         
 Senior Vice President Finance (Principal Financial and Accounting Officer) | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | Date             
 November 7, 2025 
 November 7, 2025 | ​ 
 ​ 
 ​ |
|:--|:------------------|:--|:--|:---------------------------------------------------------------------------|:--|:--|:-----------------|:--|
| ​ | *                 
 ​                 
 Khalid Islam      | ​ | ​ | Director                                                                   | ​ | ​ | November 7, 2025 | ​ |
| ​ | *                 
 ​                 
 Dov Goldstein     | ​ | ​ | Director                                                                   | ​ | ​ | November 7, 2025 | ​ |
| ​ | *                 
 ​                 
 Hans Peter Hasler | ​ | ​ | Director                                                                   | ​ | ​ | November 7, 2025 | ​ |
| ​ | *                 
 ​                 
 Gwen Melincoff    | ​ | ​ | Director                                                                   | ​ | ​ | November 7, 2025 | ​ |
| ​ | *                 
 ​                 
 Claude Nicaise    | ​ | ​ | Director                                                                   | ​ |